Nuvalent is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for oncology, with a particular focus on designing brain-penetrant, resistance-selective compounds. Its lead programs target ROS1 and ALK in non-small cell lung cancer, with additional programs in HER2 and KRAS. The company has positioned its chemistry platform to address the dual challenges of kinase resistance and CNS metastases, and in June 2026 signed a partnership with GSK giving GSK ex-US rights to two of its kinase inhibitors in a deal structured to take advantage of a post-ASCO share-price dip.
Company Info
Upcoming Milestones & Key Dates
GSK partnership close for ex-US rights to NVL-520 and NVL-655
Updated ARROS-1 and ALKOVE-1 dose-expansion data
Clinical Development Pipeline
Recent News
GSK structured a recent deal with Nuvalent to take advantage of a post-ASCO share-price dip, locking in a lower entry valuation for a partnership that gives GSK ex-US rights to two of Nuvalent's kinase inhibitors.
Leadership Team
Co-Founder, Chief Executive Officer and Chief Scientific Officer
Senior Vice President, Clinical Development
Careers & Job Openings